Incidence, Risk Factors, and Management of Conjunctivitis in Atopic Dermatitis Patients Treated With Dupilumab or Tralokinumab: Results From a Multicenter, Observational, Retrospective Study.

Background: Conjunctivitis is among the most frequent adverse events (AEs) emerged in clinical trials for all biologic drugs approved for atopic dermatitis (AD). However, real-world comparative data on the incidence, risk factors, and management of conjunctivitis remain limited.

Objective: We aimed to compare the incidence, clinical features, and management of conjunctivitis in patients with moderate-to-severe AD treated with dupilumab or tralokinumab in a real-life setting.

Clinical, Dermoscopic, and Histopathological Features of Spitzoid Lesions in Adult Patients: Insights from a Retrospective Study.

Introduction: Spitzoid lesions are a group of melanocytic tumors, including Spitz nevi, atypical Spitz tumors, and Spitz melanomas, that pose a considerable diagnostic challenge.

Objectives: Our aim was to describe the clinical, dermoscopic, and histopathological characteristics of spitzoid melanocytic lesions in adult patients in our center and to find possible associations between certain clinical-dermoscopic characteristics and the diagnosis of melanoma.

Methods: We conducted a single-center retrospective study and included all cases of histopathologically-confirmed spitzoid melanocytic lesions diagnosed in adult patients between January 2012 and December 2022.

JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis).

Introduction: Janus kinase (JAK) inhibitors are effective systemic treatments for moderate-to-severe atopic dermatitis (AD), rapidly controlling symptoms and improving quality of life. However, the impact of body mass index (BMI) on therapeutic response remains unclear.

Methods: This multicenter retrospective study analyzed data from 388 adult AD patients treated with upadacitinib, abrocitinib, or baricitinib across 25 Italian dermatology centers between May 2022 and July 2024.

Therapeutic Outcomes Across JAK Inhibitors in Prurigo Nodularis.

Background: Prurigo nodularis (PN) is a debilitating skin condition. When inadequate disease control is achieved or other systemic therapies are contraindicated, JAK inhibitors may be considered although real-world evidence remains limited.

Objective: To investigate clinical findings and treatment outcomes among patients diagnosed with PN and undergoing JAK inhibitors in real-world setting.

Clinical Course of Atopic Dermatitis after Dupilumab Discontinuation: A Multicenter Real-World Study.

Introduction: Limited data exist on the clinical course of atopic dermatitis (AD) after the discontinuation of dupilumab. This study aims to assess disease progression following dupilumab discontinuation.

Methods: A multicenter, retrospective study was conducted on 208 patients with severe AD who discontinued dupilumab for reasons unrelated to inefficacy.

The Italian Trend of Contact Allergy to 2-Hydroxyethyl Methacrylate: Is the Current European Legislation Working?

Background: (Meth)acrylates are well-known causes of allergic contact dermatitis, and nail products are the major source of exposure, especially in a non-occupational setting. In 2020, the European legislation restricted 2-hydroxyethyl methacrylate (2-HEMA) only in nail cosmetics to professional use.

Objective: To investigate the Italian prevalence trend of positive patch test reactions to 2-HEMA, the best marker for delayed hypersensitivity to (meth)acrylates.

Frequency and clinical features of disease flares in patients with atopic dermatitis treated with dupilumab.

Background: Dupilumab, an interleukin 4 (IL-4) receptor α-antagonist approved for the treatment of atopic dermatitis, is considered effective in preventing disease recurrences. However, the incidence and characteristics od atopic dermatitis flares during treatment with dupilumab in a real-life setting have not been described in the literature.

Objective: This study aims to evaluate the prevalence of disease flares in patients in treatment with dupilumab and to describe the features of flares in our study population.

Effectiveness of Tralokinumab Across Atopic Dermatitis Phenotypes.

: Tralokinumab, a fully human monoclonal antibody targeting IL-13, has shown efficacy and safety in clinical trials and real-life studies for atopic dermatitis (AD). However, data on its effectiveness across AD phenotypes are limited. : A multicentric study evaluated tralokinumab's efficacy over 52 weeks in 416 severe AD patients.

Stevens-Johnson Syndrome and Erythema Multiforme Induced by Imiquimod 5% Cream.

Introduction: Topical imiquimod is a safe and effective treatment for actinic keratoses, superficial basal cell carcinomas, and anogenital warts. The treatment is commonly associated with local inflammatory reactions, while systemic side effects are rare and generally mild. Only few cases of erythema multiforme and Stevens-Johnson syndrome have been described in association with topical imiquimod application.

Prevalence of Contact Allergy to Propolis-Testing With Different Propolis Patch Test Materials.

Introduction: Propolis is a sticky substance produced by honeybees from plant resins collected from locally growing vegetation. Its chemical composition varies depending on the plant species visited by the bees. Contact dermatitis is commonly reported following exposure to cosmetics containing propolis or following the intake of food supplements.

Efficacy and drug survival of tralokinumab in patients with severe atopic dermatitis: an 18-month multicentre study.

Background: Tralokinumab has demonstrated efficacy in the treatment of atopic dermatitis (AD) in clinical trials and real-world settings. However, there are limited data regarding the long-term use of tralokinumab in real-world settings. Here, we report the findings of a multicentre Italian study conducted to address this knowledge gap.

Stevens-Johnson induced by imiquimod 5% cream: a case report.

Imiquimod 5% cream is an approved treatment for actinic keratoses, superficial basal cell carcinomas, and anogenital warts. Severe systemic side effects associated with imiquimod 5% cream are rare, although a few cases of erythema multiforme and Stevens-Johnson syndrome have been described. We present a case of Stevens-Johnson syndrome associated with topical treatment with imiquimod of two superficial basal cell carcinomas.

The new Italian SIDAPA Baseline Series for patch testing (2023): an update according to the new regulatory pathway for contact allergens.

Allergic contact dermatitis (ACD) is a common inflammatory skin disease caused by delayed hypersensitivity to chemical and biotic contact allergens. ACD significantly affects the patients' quality of life negatively impacting both occupational and non-occupational settings. Patch testing is the gold standard diagnostic in vivo test to precise the ACD etiology and to correctly perform prevention.

The impact of occlusive vs non-occlusive application of methyl aminolevulinate on the efficacy and tolerability of daylight photodynamic therapy for actinic keratosis.

Background: Conventional photodynamic therapy (c-PDT) is an effective treatment for actinic keratoses (AKs) and nonmelanoma skin cancer which exploits the photosensitizing properties of methyl aminolaevulinate (MAL). Daylight photodynamic therapy (DL-PDT) is an alternative to c-PDT which does not require the application of MAL in occlusion and that is better tolerated by patients. The impact of occlusion on the efficacy of DL-PD has not been investigated by previous studies.